Table1.
Baseline Characteristics of the Recruited Patients in the Study*
| All(n = 770) | Men (n = 367) | Women (n = 403) | P Value | |
|---|---|---|---|---|
| Age (y) | 45.34±5.75 | 41.13±3.34 | 49.18±4.71 | < 0.001 |
| Risk Factors | ||||
| Positive Family History | 347 (45.1) | 156 (42.5) | 191 (47.4) | 0.173 |
| Hypertension | 366 (47.5) | 108 (29.4) | 258 (64.0) | < 0.001 |
| Hyperlipidemia | 555 (72.1) | 255 (69.5) | 300 (74.4) | 0.125 |
| Diabetes Mellitus | 257 (33.4) | 60 (16.3) | 197 (48.9) | < 0.001 |
| Cigarette Smoking | 265 (34.4) | 238 (64.9) | 27 (6.7) | < 0.001 |
| Opium Usage | 77 (10.0) | 75 (20.4) | 2 (0.5) | < 0.001 |
| No Risk Factor | 29 (3.8) | 17 (4.6) | 12 (3.0) | 0.228 |
| BMI (kg/m2) | 29.23±4.82 | 28.11±3.97 | 30.25±5.29 | < 0.001 |
| BMI Categories | < 0.001 | |||
| Underweight | 2 (0.3) | 1(0.3) | 1 (0.2) | |
| Normal | 133 (17.3) | 76 (20.7) | 57 (14.1) | |
| Overweight | 338 (43.9) | 182 (49.6) | 156 (38.7) | |
| Obese | 297 (38.6) | 108 (29.4) | 189 (46.9) | |
| Creatinine(mg/dl) | 0.94±0.26 | 1.03±0.21 | 0.86±0.21 | < 0.001 |
| EF (%) | 52.87±9.92 | 51.15±10.02 | 54.41±9.58 | < 0.001 |
| Abdominal Circumference (cm) | 98.94±11.77 | 98.13±9.36 | 99.69±13.60 | 0.068 |
| Recent MI | 342 (44.4) | 225 (61.3) | 117 (29.0) | < 0.001 |
| No. of Involved Vessels | 0.001 | |||
| SVD | 356 (46.2) | 146 (39.8) | 210 (52.1) | |
| 2VD | 208 (27.0) | 105 (28.6) | 103 (25.6) | |
| 3VD | 206 (26.8) | 116 (31.6) | 90 (22.3) | |
| LeftMain CoronaryInvolvement | 11 (1.4) | 4 (1.1) | 7 (1.7) | 0.450 |
| Initial Treatment | 0.245 | |||
| Medical Treatment | 238 (30.9) | 103 (28.1) | 135 (33.5) | |
| PCI | 349 (45.3) | 171 (46.6) | 178 (44.2) | |
| CABG | 183 (23.8) | 93 (25.3) | 90 (22.3) | |
| MACE | 152 (19.7) | 66 (18.0) | 86 (21.3) | 0.243 |
| Duration of F/U (mo) | 60.43±44.32 | 58.96±20.92 | 61.77±57.94 | 0.381 |
BMI, Body mass index; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-vessel disease; 3VD, Three-vessel disease; PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; MACE; Major adverse cardiac events; F/U, Follow-up
*
Data are presented as mean± SD or n (%)